Noetic Commits to Investing $6.95M into Seed Round for The Alexander Shulgin Research Institute for Psychedelic Drug Discovery and Development

The PR

TORONTO, ON / ACCESSWIRE / December 9, 2021 / Noetic Fund led the Seed round for the Alexander Shulgin Research Institute Inc. (“ASRI”), a psychedelic drug discovery company focused on the design, chemical synthesis, and pharmacological evaluation of novel compounds, as well as characterization of compounds from the Shulgin Vault, which contains hundreds of compounds created by Sasha Shulgin before his passing. The total Seed financing round completed at $7.2 million.

About Noetic

Noetic was founded in early 2020 by veteran investors with the professional background, experience, and network required to navigate the nascent psychedelic sector and to foster immense growth by backing compelling science and talented entreprenuers.

Noetic is committed to investing in the development of pure, innovative and sustainable products and services in the emerging market of bioavailable psychedelic plants. It has to date, supported 6 companies to go public from their Fund I initiative.

About ASRI

The Alexander Shulgin Research Institute Inc. (“ASRI”) is a psychedelics discovery, development, and educational organization dedicated to continuing and extending the work of Dr Alexander “Sasha” Shulgin. The Institute was informally founded by Dr. Shulgin in the 1980s to spotlight his research. After his passing in 2014, his research colleagues Paul F. Daley, Ph.D., and Nicholas V. Cozzi, Ph.D. adopted leadership roles at the Institute. ASRI has since synthesized and supplied compounds for basic chemical, pharmacological, and clinical studies at universities and research organizations around the world, including recent FDA-approved clinical research with psilocybin and DMT. The ASRI was formally incorporated by Daley, Cozzi, and Shulgin’s widow and ASRI co-founder, Ann Shulgin, on April 19, 2021.

Primary Sponsor

Top Marijuana Blog